| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab109324-10μl | 10μl | In stock | $69.90 | |
| Ab109324-50μl | 50μl | In stock | $209.90 | |
| Ab109324-100μl | 100μl | In stock | $299.90 | |
| Ab109324-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,299.90 |
mAb (C12); Mouse anti Human IDH1 Antibody; WB, IHC; Unconjugated
| Product Name | IDH1 Mouse mAb - Primary antibody, specific to IDH1, Mouse IgG1 |
|---|---|
| Synonyms | Cytosolic NADP isocitrate dehydrogenase antibody | Cytosolic NADP-isocitrate dehydrogenase antibody | Epididymis luminal protein 216 antibody | Epididymis secretory protein Li 26 antibody | HEL-216 antibody | HEL-S-26 antibody | ICDH antibody | IDCD antib |
| Specifications & Purity | Carrier Free, ExactAb™, Validated, High Performance, See COA |
| Host species | Mouse |
| Specificity | IDH1 |
| Immunogen | Recombinant IDH1 expressed in E.coli (AA 74-333). |
| Positive Control | WB: Hep G2 and NIH/3T3 cell lysates. IHC: Human colorectal cancer, stomach, kidney, prostate, glioma tissues. |
| Conjugation | Unconjugated |
| Grade | Carrier Free, ExactAb™, High Performance, Validated |
| Product Description | Mouse anti Human IDH1 Antibody, Monoclonal antibody (C12), could be used for WB,IHC and so on. |
| Isotype | Mouse IgG2a |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 150 kDa |
| Purification Method | Protein A + Protein G purified |
| Form | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle. |
IDH1 Mouse mAb (Ab109324) - Western Blot
All lanes: IDH1 Mouse mAb (Ab109324) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Mouse IgG H&L (HRP) (Ab138040) at 1/40000 dilution
Predicted band size: 47 kDa
Observed band size: 44 kDa
Exposure time: 25.4 s
IDH1 Mouse mAb (Ab109324) - IHC
DAB staining on IHC
Sample: Human Colorectal cancer Tissue
Primary Ab: 30 µg/mL IDH1 Mouse mAb (Ab109324)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody.
IDH1 Mouse mAb (Ab109324) - IHC
DAB staining on IHC
Sample: Human Stomach Tissue
Primary Ab: 30 µg/mL IDH1 Mouse mAb (Ab109324)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody.
IDH1 Mouse mAb (Ab109324) - IHC
DAB staining on IHC
Sample: Human Kidney Tissue
Primary Ab: 30 µg/mL IDH1 Mouse mAb (Ab109324)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody.
IDH1 Mouse mAb (Ab109324) - IHC
DAB staining on IHC
Sample: Human Prostate Tissue
Primary Ab: 30 µg/mL IDH1 Mouse mAb (Ab109324)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody.
IDH1 Mouse mAb (Ab109324) - IHC
DAB staining on IHC
Sample: Human Glioma Tissue
Primary Ab: 30 µg/mL IDH1 Mouse mAb (Ab109324)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody.
IDH1 Mouse mAb (Ab109324) - IHC
DAB staining on IHC
Sample: Human Prostate Tissue
Primary Ab: 30 µg/mL IDH1 Mouse mAb (Ab109324)
Control: Used PBS instead of primary antibody
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody.
IDH1 Mouse mAb (Ab109324) - IHC
DAB staining on IHC
Sample: Human Kidney Tissue
Primary Ab: 30 µg/mL IDH1 Mouse mAb (Ab109324)
Control: Used PBS instead of primary antibody
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Application | Dilution info |
|---|---|
| IHC | 5-30 µg/mL |
| WB |
0.01-2 µg/mL
|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0303945 | Certificate of Analysis | Mar 31, 2024 | Ab109324 |
| ZJ24F0303944 | Certificate of Analysis | Mar 31, 2024 | Ab109324 |
| ZJ24F0303943 | Certificate of Analysis | Mar 31, 2024 | Ab109324 |
| 1. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions.. Science, 325 (5942): (834-40). [PMID:19608861] [10.1021/op500134e] |
| 2. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC et al.. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.. Nature, 462 (7274): (739-44). [PMID:19935646] [10.1021/op500134e] |
| 3. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ et al.. (2015) New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.. Nat Chem Biol, 11 (11): (878-86). [PMID:26436839] [10.1021/op500134e] |
| 4. Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D et al.. (2018) Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.. ACS Med Chem Lett, 9 (4): (300-305). [PMID:29670690] [10.1021/op500134e] |
| 5. Zhao Q, Manning JR, Sutton J, Costales A, Sendzik M, Shafer CM, Levell JR, Liu G, Caferro T, Cho YS et al.. (2018) Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.. ACS Med Chem Lett, 9 (7): (746-751). [PMID:30034612] [10.1021/op500134e] |
| 6. Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, Wang Z, Castro J, Clarke A, Gotur D et al.. (2020) Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.. J Med Chem, 63 (4): (1612-1623). [PMID:31971798] [10.1021/op500134e] |
| 7. Machida Y, Nakagawa M, Matsunaga H, Yamaguchi M, Ogawara Y, Shima Y, Yamagata K, Katsumoto T, Hattori A, Itoh M et al.. (2020) A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.. Mol Cancer Ther, 19 (2): (375-383). [PMID:31727689] [10.1021/op500134e] |
| 8. Zheng B, Yao Y, Liu Z, Deng L, Anglin JL, Jiang H, Prasad BV, Song Y.. (2013) Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.. ACS Med Chem Lett, 4 (6): (542-546). [PMID:23795241] [10.1021/ml400036z] |
| 9. Liu Z, Yao Y, Kogiso M, Zheng B, Deng L, Qiu JJ, Dong S, Lv H, Gallo JM, Li XN, Song Y.. (2014) Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.. J Med Chem, 57 (20): (8307-8318). [PMID:25271760] [10.1021/jm500660f] |
| 10. Wu F, Jiang H, Zheng B, Kogiso M, Yao Y, Zhou C, Li XN, Song Y.. (2015) Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.. J Med Chem, 58 (17): (6899-6908). [PMID:26280302] [10.1021/acs.jmedchem.5b00684] |
| 11. Rai G, Brimacombe KR, Mott BT, Urban DJ, Hu X, Yang SM, Lee TD, Cheff DM, Kouznetsova J, Benavides GA, Pohida K, Kuenstner EJ, Luci DK, Lukacs CM, Davies DR, Dranow DM, Zhu H, Sulikowski G, Moore WJ, Stott GM, Flint AJ, Hall MD, Darley-Usmar VM, Neckers LM, Dang CV, Waterson AG, Simeonov A, Jadhav A, Maloney DJ.. (2017) Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH).. J Med Chem, 60 (22): (9184-9204). [PMID:29120638] [10.1021/acs.jmedchem.7b00941] |
| 12. Cho YS, Levell JR, Liu G, Caferro T, Sutton J, Shafer CM, Costales A, Manning JR, Zhao Q, Sendzik M, Shultz M, Chenail G, Dooley J, Villalba B, Farsidjani A, Chen J, Kulathila R, Xie X, Dodd S, Gould T, Liang G, Heimbach T, Slocum K, Firestone B, Pu M, Pagliarini R, Growney JD.. (2017) Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor.. ACS Med Chem Lett, 8 (10): (1116-1121). [PMID:29057061] [10.1021/acsmedchemlett.7b00342] |
| 13. Ma T, Zou F, Pusch S, Yang L, Zhu Q, Xu Y, Gu Y, von Deimling A, Zha X.. (2017) Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.. Bioorg Med Chem, 25 (24): (6379-6387). [PMID:29089260] [10.1016/j.bmc.2017.10.009] |
| 14. Zou F, Pusch S, Hua J, Ma T, Yang L, Zhu Q, Xu Y, Gu Y, von Deimling A, Zha X.. (2018) Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.. Bioorg Med Chem Lett, 28 (3): (388-393). [PMID:29290542] [10.1016/j.bmcl.2017.12.030] |
| 15. Crane EA, Heydenreuter W, Beck KR, Strajhar P, Vomacka J, Smiesko M, Mons E, Barth L, Neuburger M, Vedani A, Odermatt A, Sieber SA, Gademann K.. (2019) Profiling withanolide A for therapeutic targets in neurodegenerative diseases.. Bioorg Med Chem, 27 (12): (2508-2520). [PMID:30929949] [10.1016/j.bmc.2019.03.022] |
| 16. Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.. (2019) Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells.. Bioorg Med Chem Lett, 29 (17): (2503-2510). [PMID:31327531] [10.1016/j.bmcl.2019.07.011] |
| 17. Lin J, Lu W, Caravella JA, Campbell AM, Diebold RB, Ericsson A, Fritzen E, Gustafson GR, Lancia DR, Shelekhin T, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Diep H, Kershaw M, Yao L, Kauffman G, Hubbs SE, Luke GP, Toms AV, Wang L, Bair KW, Barr KJ, Dinsmore C, Walker D, Ashwell S.. (2019) Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.. J Med Chem, 62 (14): (6575-6596). [PMID:31199148] [10.1021/acs.jmedchem.9b00362] |
| 18. Duan Z, Liu J, Niu L, Wang J, Feng M, Chen H, Luo C.. (2019) Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.. Bioorg Med Chem, 27 (15): (3229-3236). [PMID:31208797] [10.1016/j.bmc.2019.05.040] |
| 19. Cao H, Zhu G, Sun L, Chen G, Ma X, Luo X, Zhu J.. (2019) Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.. Eur J Med Chem, 183 (111694-111694). [PMID:31561044] [10.1016/j.ejmech.2019.111694] |
| 20. Hu C, Zuo Y, Liu J, Xu H, Liao W, Dang Y, Luo C, Tang L, Zhang H.. (2020) Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.. Bioorg Med Chem Lett, 30 (2): (126825-126825). [PMID:31836442] [10.1016/j.bmcl.2019.126825] |
| 21. Nekrutenko, A A, Hillis, D M DM, Patton, J C JC, Bradley, R D RD and Baker, R J RJ.. (1998) Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family.. Molecular biology and evolution, [PMID:9866202] |
| 22. Geisbrecht, B V BV and Gould, S J SJ.. (1999) The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase.. The Journal of biological chemistry, (22): [PMID:10521434] |
| 23. Wiemann, S S and 23 more authors.. (2001) Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs.. Genome research, [PMID:11230166] |
| 24. Xu, Xiang X and 6 more authors.. (2004) Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity.. The Journal of biological chemistry, (6): [PMID:15173171] |
| 25. Hillier, Ladeana W LW and 121 more authors.. (2005) Generation and annotation of the DNA sequences of human chromosomes 2 and 4.. Nature, (7): [PMID:15815621] |
| 26. Sjöblom, Tobias T and 28 more authors.. (2006) The consensus coding sequences of human breast and colorectal cancers.. Science (New York, N.Y.), (13): [PMID:16959974] |
| 27. Bechtel, Stephanie S and 18 more authors.. (2007) The full-ORF clone resource of the German cDNA Consortium.. BMC genomics, (31): [PMID:17974005] |
| 28. Parsons, D Williams DW and 32 more authors.. (2008) An integrated genomic analysis of human glioblastoma multiforme.. Science (New York, N.Y.), (26): [PMID:18772396] |
| 29. Bleeker, Fonnet E FE and 16 more authors.. (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.. Human mutation, [PMID:19117336] |
| 30. Van Damme, Petra P and 15 more authors.. (2012) N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.. Proceedings of the National Academy of Sciences of the United States of America, (31): [PMID:22814378] |
| 31. Davis, Mindy I MI and 14 more authors.. (2014) Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.. The Journal of biological chemistry, (16): [PMID:24668804] |
| 32. Jin, Yonghui Y and 13 more authors.. (2015) Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.. PloS one, [PMID:26161668] |
| 33. Thomas R Burkard,Melanie Planyavsky,Ines Kaupe,Florian P Breitwieser,Tilmann Bürckstümmer,Keiryn L Bennett,Giulio Superti-Furga,Jacques Colinge. (2011-01-29) Initial characterization of the human central proteome.. BMC systems biology, 5 (17-17). [PMID:21269460] |
